JP2002509153A5 - - Google Patents

Download PDF

Info

Publication number
JP2002509153A5
JP2002509153A5 JP2000540142A JP2000540142A JP2002509153A5 JP 2002509153 A5 JP2002509153 A5 JP 2002509153A5 JP 2000540142 A JP2000540142 A JP 2000540142A JP 2000540142 A JP2000540142 A JP 2000540142A JP 2002509153 A5 JP2002509153 A5 JP 2002509153A5
Authority
JP
Japan
Prior art keywords
compound
interleukin
converting enzyme
treating
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2000540142A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002509153A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/024848 external-priority patent/WO1999036426A1/en
Publication of JP2002509153A publication Critical patent/JP2002509153A/ja
Publication of JP2002509153A5 publication Critical patent/JP2002509153A5/ja
Abandoned legal-status Critical Current

Links

JP2000540142A 1998-01-20 1998-11-20 インターロイキン−1β変換酵素(ICE)のインビボ阻害剤としてのN−[2−(5−ベンジルオキシカルボニル−アミノ−6−オキソ−2−(4−フルオロフェニル)−1,6−ジヒドロ−1−ピリミジニル)アセトキシル]−L−アスパラギン酸アルデヒド Abandoned JP2002509153A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7191898P 1998-01-20 1998-01-20
US60/071,918 1998-01-20
PCT/US1998/024848 WO1999036426A1 (en) 1998-01-20 1998-11-20 N-[2-(5-BENZYLOXYCARBONYL-AMINO-6-OXO-2-(4-FLUOROPHENYL)-1,6-DIHYDRO-1-PYRIMIDINYL)ACETO- XYL]-L-ASPARTIC ACID ALDEHYDE AS AN IN VIVO INHIBITOR OF INTERLEUKIN-1β CONVERTING ENZYME (ICE)

Publications (2)

Publication Number Publication Date
JP2002509153A JP2002509153A (ja) 2002-03-26
JP2002509153A5 true JP2002509153A5 (US07794700-20100914-C00152.png) 2006-01-19

Family

ID=22104428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000540142A Abandoned JP2002509153A (ja) 1998-01-20 1998-11-20 インターロイキン−1β変換酵素(ICE)のインビボ阻害剤としてのN−[2−(5−ベンジルオキシカルボニル−アミノ−6−オキソ−2−(4−フルオロフェニル)−1,6−ジヒドロ−1−ピリミジニル)アセトキシル]−L−アスパラギン酸アルデヒド

Country Status (11)

Country Link
EP (1) EP1049703B1 (US07794700-20100914-C00152.png)
JP (1) JP2002509153A (US07794700-20100914-C00152.png)
AT (1) ATE232536T1 (US07794700-20100914-C00152.png)
AU (1) AU1466399A (US07794700-20100914-C00152.png)
CA (1) CA2309546A1 (US07794700-20100914-C00152.png)
DE (1) DE69811404T2 (US07794700-20100914-C00152.png)
DK (1) DK1049703T3 (US07794700-20100914-C00152.png)
ES (1) ES2193589T3 (US07794700-20100914-C00152.png)
PT (1) PT1049703E (US07794700-20100914-C00152.png)
WO (1) WO1999036426A1 (US07794700-20100914-C00152.png)
ZA (1) ZA99369B (US07794700-20100914-C00152.png)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6693121B2 (en) 2000-04-05 2004-02-17 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
AU2001249870A1 (en) 2000-04-05 2001-10-23 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
WO2001079155A2 (en) 2000-04-17 2001-10-25 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
WO2001087851A1 (en) * 2000-05-18 2001-11-22 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
WO2002006242A2 (en) * 2000-07-18 2002-01-24 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
WO2002042272A2 (en) 2000-11-20 2002-05-30 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
ATE464068T1 (de) 2001-06-26 2010-04-15 Amgen Fremont Inc Antikörper gegen opgl
MXPA04003163A (es) 2001-10-03 2004-07-08 Pharmacia Corp Compuestos heterociclicos de 6 elementos utiles para inhibicion selectiva de la casdada de coagulacion.
WO2003093242A2 (en) 2001-10-03 2003-11-13 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
EA033750B1 (ru) 2002-09-06 2019-11-21 Amgen Inc Изолированная молекула нуклеиновой кислоты, кодирующая антитело человека к рецептору интерлейкина-1, и ее применение
CN1950364B (zh) 2004-03-12 2011-06-08 弗特克斯药品有限公司 制备天冬氨酸缩醛胱冬酶抑制剂的方法和中间体
EP1750689A1 (en) 2004-05-15 2007-02-14 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
EP1778221A2 (en) 2004-05-27 2007-05-02 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
ATE529430T1 (de) 2005-07-28 2011-11-15 Vertex Pharma Caspase-hemmer-propharmaka
US9116157B2 (en) 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441960A (en) * 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
NZ283876A (en) * 1994-03-31 2001-03-30 Vertex Pharma Pyrimidinyl derivatives as interleukin inhibitors

Similar Documents

Publication Publication Date Title
JP2002509153A5 (US07794700-20100914-C00152.png)
CA2378469A1 (en) An oral solid composition comprising carbidopa, levodopa and entacapone
DE69936848D1 (de) Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie
ZA977783B (en) Method of inhibiting fibrosis with a somatostatin agonist
EP1127579A3 (en) Method for increasing bioavailability of oral pharmaceutical compositions
MY127946A (en) Therapeutic formulation for administering tolterodine with controlled release
IL150307A0 (en) Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected being caused by the drug
TW200505900A (en) Muscarinic agonists
LU91181I2 (fr) Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt).
PL321498A1 (en) Pharmaceutic agent for use against urine incontinence and method of obtaining (s)-desethyloxybutinine
JP2002531505A5 (US07794700-20100914-C00152.png)
JP2002510633A5 (US07794700-20100914-C00152.png)
JP2002522501A5 (US07794700-20100914-C00152.png)
JP2002518502A5 (US07794700-20100914-C00152.png)
JP2002520286A5 (US07794700-20100914-C00152.png)
WO2002056745A3 (en) Method of treating parkinson's disease
WO2003015690A3 (en) Method for treating primary insomnia
JP2002537256A5 (US07794700-20100914-C00152.png)
JP2005513036A5 (US07794700-20100914-C00152.png)
EP0985414A3 (en) Method of treating glaucoma and ischemic retinopathy
EP1270000A3 (en) Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
JP2002533400A5 (US07794700-20100914-C00152.png)
WO1998031355A3 (en) Pharmaceutical composition comprising n-propylnorapomorphine and cathecol-o-methyl-transferase inhibitor for treating parkinson's disease
HRP20080389A2 (en) THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
EP0790250A3 (en) Inhibitors of biogenic amine transporters